Md Nahidul Wari1, Archana George Vallonthaiel1, Aijaz Ahmed1, Deepali Saxena1, Venkateswaran K Iyer2, Sandeep R Mathur1, Sandeep Agarwala3, Sameer Bakhshi4, V Srinivas5, P Chattopadhyaya6, Arundhati Sharma7, S Datta Gupta1, Amit Dinda1. 1. Department of Pathology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India. 2. Department of Pathology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India. iyer_venkat@hotmail.com. 3. Department of Paediatric Surgery, All India Institute of Medical Sciences, New Delhi, India. 4. Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India. 5. Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, India. 6. Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India. 7. Department of Anatomy, All India Institute of Medical Sciences, New Delhi, India.
Abstract
PURPOSE: To correlate expression of Glypican-3 in Wilms tumor with histopathology, stage, and outcome. METHODS: Glypican-3 mRNA expression by real-time PCR on tumor and normal germline samples from 75 fresh nephrectomies for Wilms tumor with fold change after normalization against GAPDH was compared. Survival analysis for event-free and overall survival (EFS, OS) with 2-year follow-up for Glypican-3 overexpression (>1.5 times) and clinicopathological parameters was performed. RESULTS: Glypican-3 was overexpressed in 37/75 (49.3%). It was overexpressed in 77% (10/13) cases with blastema predominance or anaplastic histology, as compared to 44% of other histologies (27/62) (p = 0.03). OS was 73 and 93%, respectively (p = 0.016), for those with and without GPC-3 overexpression. EFS was not significantly different with Glypican-3 overexpression (p = 0.11). All 5 deaths among blastema predominant tumors and 4/5 deaths among triphasic tumors had overexpressed Glypican-3. Most deaths in Stage IV, Stage III, and Stage I + II (5/7, 3/3, 1/1) had GPC-3 overexpression. On multivariate analysis, only histology and stage were found to have independent prognostic value. CONCLUSION: Glypican-3 overexpression in Wilms tumor correlates with poor OS on univariate analysis. However, only histology and stage have independent prognostic value. Glypican-3 levels may help to stratify intermediate outcome histology (triphasic) and Stage III Wilms tumors.
PURPOSE: To correlate expression of Glypican-3 in Wilms tumor with histopathology, stage, and outcome. METHODS:Glypican-3 mRNA expression by real-time PCR on tumor and normal germline samples from 75 fresh nephrectomies for Wilms tumor with fold change after normalization against GAPDH was compared. Survival analysis for event-free and overall survival (EFS, OS) with 2-year follow-up for Glypican-3 overexpression (>1.5 times) and clinicopathological parameters was performed. RESULTS:Glypican-3 was overexpressed in 37/75 (49.3%). It was overexpressed in 77% (10/13) cases with blastema predominance or anaplastic histology, as compared to 44% of other histologies (27/62) (p = 0.03). OS was 73 and 93%, respectively (p = 0.016), for those with and without GPC-3 overexpression. EFS was not significantly different with Glypican-3 overexpression (p = 0.11). All 5 deaths among blastema predominant tumors and 4/5 deaths among triphasic tumors had overexpressed Glypican-3. Most deaths in Stage IV, Stage III, and Stage I + II (5/7, 3/3, 1/1) had GPC-3 overexpression. On multivariate analysis, only histology and stage were found to have independent prognostic value. CONCLUSION:Glypican-3 overexpression in Wilms tumor correlates with poor OS on univariate analysis. However, only histology and stage have independent prognostic value. Glypican-3 levels may help to stratify intermediate outcome histology (triphasic) and Stage III Wilms tumors.
Authors: A Weirich; I Leuschner; D Harms; G M Vujanic; J Tröger; U Abel; N Graf; D Schmidt; R Ludwig; P A Voûte Journal: Ann Oncol Date: 2001-03 Impact factor: 32.976
Authors: G Pilia; R M Hughes-Benzie; A MacKenzie; P Baybayan; E Y Chen; R Huber; G Neri; A Cao; A Forabosco; D Schlessinger Journal: Nat Genet Date: 1996-03 Impact factor: 38.330
Authors: Young Kwan Sung; Sun Young Hwang; Mi Kyung Park; Mohammad Farooq; In Sook Han; Han Ik Bae; Jung-Chul Kim; Moonkyu Kim Journal: Cancer Sci Date: 2003-03 Impact factor: 6.716